01
Adults are seeking evaluation.
About half of U.S. adults with a current ADHD diagnosis were diagnosed as adults.
SourceCDC, MMWR, 2024
For investors
Cognitive testing that clinicians order by link.
ATTNhealth is an early-stage company building a browser-based neurocognitive assessment for clinicians to order and patients to complete at home: ADHD first, then cognitive decline, with 510(k) as the planned pathway for the ADHD battery. It's in development and not FDA cleared. This page sets out the plan. Detailed materials are available on request.
In developmentNot FDA clearedNot for clinical use: read our regulatory statusMillions of attention and memory questions. Few objective answers.
Objective cognitive tests exist, including FDA-cleared computerized tests used in clinics and at home. Even so, many attention and memory concerns are still evaluated with interviews and rating scales alone.
15.5million
U.S. adults with a current ADHD diagnosis; about half diagnosed as adults.
SourceCDC, MMWR, 2024
7.1million
U.S. children ages 3–17 ever diagnosed with ADHD (2022). Pediatric use would be a later step; our first studies are planned in adults.
7.4million
Americans 65+ living with Alzheimer's dementia in 2026, projected to reach nearly 13 million by 2050.
<1 in 3
Fewer than one in three Medicare beneficiaries 65 and older in a national internet-panel survey (through 2019) reported a structured cognitive assessment, despite Medicare's Annual Wellness Visit requirement.
Market sizing and unit economics are in the materials available on request.
What exists, and where we fit.
FDA-cleared computerized attention tests already run in clinics and, with a webcam, at home. Computerized cognitive batteries, many of them FDA-regulated, are used for memory concerns. ATTNhealth isn't trying to be the first test in a browser. The aim is one camera-free browser battery for both clinical questions, starting with ADHD, with a report layer for the ordering clinician and a workflow designed around how clinics order and bill.
Two bets we'll test in the pilot: that a camera-free test is easier for clinics and patients to accept at home, and that primary care, which fields both adult ADHD questions and Medicare's requirement to detect cognitive impairment, wants one ordering flow for both. Cleared webcam tests also measure movement; ours won't, so its picture of ADHD will be narrower.
Already on the market
- FDA-cleared attention tests. Computerized continuous performance tests, run in clinic or at home. Qbtech's QbCheck, for example, runs in a browser with a webcam, takes about 15–20 minutes, and is cleared for ages 6–60. Cleared tests in this category typically take 15–25 minutes.
- Computerized cognitive batteries. BrainCheck, Cognivue, and Creyos offer computerized cognitive assessments that their makers describe as FDA-regulated Class II devices (computerized cognitive assessment aids, 21 CFR 882.1470). Cognivue was authorized through FDA's De Novo pathway in 2015. CNS Vital Signs offers multi-domain computerized testing.
- Full neuropsychological evaluation. The broadest assessment, delivered by a specialist, often over several hours.
Product details are summarized from the companies' public materials. Each product's labeling governs its uses.
One battery, two clinical questions.
ADHD and cognitive decline share core measures: attention, working memory, processing speed. One task engine is designed to serve the ADHD battery first, then a cognitive-decline battery with memory tasks added.
Adaptive within a standardized protocol.
The core attention task is designed to run a fixed, standardized protocol so scores can be compared with norms. Practice trials and working-memory difficulty are planned to adjust by fixed rules that are part of the protocol, so the norms cover them too.
A report layer for the ordering clinician.
Validity first, then domain scores, then the measures underneath. Later, AI-drafted interpretive notes that the clinician reviews, edits, and signs, and models that flag disengagement for validity review. Never diagnosis.
Designed around the clinic.
Ordered like a lab test, completed on a modern laptop or desktop with no camera or install, and designed to fit existing CPT codes for automated test administration and clinician interpretation.
What compounds.
If the plan works, each step builds on the last: published validation, a 510(k) clearance, our own age-stratified norms, and an ordering workflow inside clinics. Consented research relating these performance measures to biological markers, such as genetic risk or blood-based Alzheimer's markers, is a long-term option, not the plan.
All of the above describes design goals. ATTNhealth is not yet validated or FDA cleared.
Clinical credibility first. Everything else after.
- Phase 1In progress
An ADHD battery, to be validated and published
The clinical wedge. Timing and reliability studies, an IRB-approved validation study in adults, and an FDA pre-submission meeting, then a 510(k) submission if the data support it.
- Phase 2Planned
A cognitive-decline battery on the same engine
Memory tasks added. Its regulatory pathway will be decided with counsel.
- Phase 3Planned
Clinician-reviewed, AI-drafted interpretation
The decision-support layer.
- Phase 4Planned
More indications
TBI, post-COVID cognitive symptoms, pre-surgical baselines, learning disorders, each only after validation.
- Phase 5Planned
Consumer and wellness
Only after clinical credibility is established. Wellness claims made before the evidence have drawn regulators' attention. We won't do it in that order.
Why now.
02
Primary care is required to look.
Medicare's Annual Wellness Visit requires detection of cognitive impairment, yet fewer than one in three beneficiaries surveyed reported a structured assessment.
03
Automated testing already has a billing code.
CPT 96146 describes a single automated test administered on an electronic platform with an automated result. It's reported once per session, however many tasks are given. It's a workflow fit, not a revenue model.
04
A cleared path exists.
Computerized attention tests have reached the market through 510(k) since at least 2004, and a 2021 FDA advisory panel recommended Class II with special controls for this device type. The classification isn't final. 510(k) is our planned pathway, and we plan an FDA pre-submission meeting to confirm the device type and requirements.
SourcesFDA Neurological Devices Panel, June 4, 2021 · FDA 510(k) K040894
05
Biology has a blood test. Function still needs a measure.
In May 2025, FDA cleared the first blood test to aid in diagnosing Alzheimer's disease, for adults already being evaluated for cognitive decline. Blood biomarkers point to pathology; clinicians still need to measure how cognition is functioning. That's the question our later cognitive-decline battery is designed for.
Why this founder
He treats it. He studies it. He's designing the test he wants to order.
ATTNhealth's founder is an MD, PhD psychiatrist and endowed associate professor of psychiatry at an Ivy League medical school. He treats adults with ADHD and has 100+ peer-reviewed publications.
Name, CV and references are shared with investors and clinical partners on request.
- ClinicalTreats adults with ADHD
- ResearchLeads an academic research lab
- Record100+ peer-reviewed publications
Academic roles are described for context only. ATTNhealth is an independent company.
Clinician-ordered. Designed to fit existing codes.
ATTNhealth is designed to be ordered by clinicians and to map to existing CPT codes for automated test administration (such as 96146, reported once per session) and for clinician interpretation. We don't treat any billing code as the business model. The revenue model is described in the materials available on request.
This is a design, not a demonstrated business.
Next milestones.
Plans, in order. Plans can change.
- A technical cofounder and the production platform
- Device-timing and test–retest reliability studies
- An IRB-approved validation study in adults referred for ADHD evaluation
- An FDA pre-submission meeting, then a 510(k) submission if the data support it
- IP filings
Request investor materials.
The deck covers the plan, market sizing, unit economics, the validation plan, and the founder's full background. The founder sends it personally.
Name, CV and references are shared with investors and clinical partners on request.
Prefer email? Write to hello@attnhealth.com.
Not an offer. Forward-looking statements. This page is for information only. It is not an offer to sell, or a solicitation of an offer to buy, any securities. Any offering will be made only through definitive documents to eligible investors. Statements about plans, product development, regulatory pathways, and milestones are forward-looking. They involve risks and uncertainties, and actual results may differ materially. ATTNhealth is in development. It is not FDA cleared or approved and is not available for clinical use.
Sources (9)
- Staley BS, et al. MMWR 2024;73(40):890–895. cdc.gov
- Danielson ML, et al. ADHD Prevalence Among U.S. Children and Adolescents in 2022. J Clin Child Adolesc Psychol 2024. PubMed 38778436
- Alzheimer's Association. 2026 Alzheimer's Disease Facts and Figures. alz.org
- Jacobson M, et al. Health Affairs 2020. PMC9517732
- 42 CFR § 410.15. ecfr.gov
- APA Services. 2026 Psychological and Neuropsychological Testing: Billing and Coding Guide. apaservices.org
- FDA Neurological Devices Panel, June 4, 2021 (24-hour summary). fda.gov
- U.S. FDA. 510(k) premarket notification K040894 (2004). accessdata.fda.gov
- U.S. FDA. FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease (press announcement, May 2025). fda.gov